Investors

News Releases

Date Title  
Toggle Summary Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa™ for Onychomycosis
SAN DIEGO, CALIFORNIA and MILTON, ONTARIO--(Marketwire - Jan. 3, 2012) - Apricus Biosciences, Inc. ("Apricus Bio") (NASDAQ:APRI) ( http://www.apricusbio.com ) and Stellar Pharmaceuticals Inc. ("Stellar Pharma") (OTCQB:SLXCF)(OTCBB:SLXCF)(PINKSHEETS:SLXCF), a Canadian public company, announced today
Toggle Summary Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck
-Acquired ZONTIVITY ® in the U.S. and Canada - -Long-range market exclusivity through regulatory exclusivity and intellectual property protection- MISSISSAUGA, Ontario , Sept. 7, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc.  (NASDAQ: ARLZ) (TSX: ARZ), a global specialty pharmaceutical company,
Toggle Summary Aralez Added To The NASDAQ Biotechnology Index
MISSISSAUGA, Ontario , Dec. 19, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ( Aralez or the Company ) today announced that it has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective as of the opening of trading on Monday, December 19, 2016 .
Toggle Summary Aralez Announces Board Member Resignation
Toggle Summary Aralez Announces Commercial Launch Of BLEXTEN™ In Canada
MISSISSAUGA, Ontario , Dec. 19, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ( Aralez or the Company ) today announced the commercial launch of BLEXTEN™ (Bilastine 20 mg oral tablet) for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic
Toggle Summary Aralez Announces Departure of Chief Financial Officer
MISSISSAUGA, Ontario , Nov. 30, 2017 /PRNewswire/ --   Aralez Pharmaceuticals Inc.   (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that Scott J. Charles , Chief Financial Officer, is leaving the Company to pursue other opportunities, effective immediately.
Toggle Summary Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents
 -Patents Covering VIMOVO Infringed by Proposed Generics Developed by Dr. Reddy's Laboratories , Mylan, and Lupin-  MISSISSAUGA, Ontario , June 27, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced that the United States District
Toggle Summary Aralez Announces FDA Acceptance of New Drug Application for YOSPRALA™
MILTON, Ontario , March 28, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company"), a global specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (" FDA ") has acknowledged acceptance of the New Drug
Toggle Summary Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
-Aralez Sales Force Will Be Expanded by 85 to 110 Sales Representatives by Launch- -YOSPRALA U.S. Commercial Launch Planned for First Week of October- -Company to Host Conference Call Today at 11:00 a.m. ET - MISSISSAUGA, Ontario , Sept. 15, 2016 /PRNewswire/ --  Aralez Pharmaceuticals Inc.
Toggle Summary Aralez Announces First Quarter 2018 Financial Results
-1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017- MISSISSAUGA, Ontario , May 8, 2018 /PRNewswire/ --  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (" Aralez " or the " Company ") today announced financial results for the first quarter ending March 31, 2018 .

Copyright West LLC. Minimum 15 minutes delayed.